IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number

: TBA

Confirmation No.:

TBA

Applicant

: Laurent DESIRE

International Filing Date

: November 5, 2004

Title

: BACE455, AN ALTERNATIVE SPLICE VARIANT OF THE

HUMAN BETA-SECRETASE

TC/Art Unit

: TBA

Examiner:

: TBA

Docket No.

: 67987.000002

Customer No.

: 21967

MAIL STOP PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants submit attached Form PTO-SB/08B (modified) for consideration and request the documents cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

The documents listed on the attached Form PTO-SB/08B were cited by the European Patent Office in the International Search Report and the Written Opinion of the International Searching Authority, dated March 9, 2005, for International Application No. PCT/IB2004/003897. A copy of the International Search Report and the Written Opinion of the International Searching Authority is enclosed herein.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings,

10/578493

PATENT APPLICATION ATTORNEY DOCKET No.: 67987.000002

IAP12 Rec'd PCT/PTO 05 MAY 2006

underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

As this application was filed after June 30, 2003, copies of U.S. patents and/or U.S. patent application publications for national stage applications under 35 U.S.C. 371 cited on the attached Form PTO-SB/08A (modified), are not being provided as specified in 1276 *O.G.* 55 (5 August 2003).

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

alexah H. In

Dated: May 5, 2006

By:

Alexander H. Spiegler Registration No. 56,625

Hunton & Williams LLP Intellectual Property Department 1900 K Street, N.W. Suite 1200 Washington, DC 20006 (202) 955-1500 (telephone) (202) 778-2201 (facsimile) RMS/AHS:sac

IAP12 Rec'd PCT/PTO 0 5 MAY 2006

PTO/SB/08B (08/03) (modified)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE тва 10/578493 Substitute for form 1449/PTO Application Number **International Filing Date** November 5, 2004 INFORMATION DISCLOSURE Laurent DESIRE First Named Inventor STATEMENT BY APPLICANT TBA Art Unit (use as many sheets as necessary) **Examiner Name TBA** Sheet 1 of 1 **Attorney Docket Number** 67987.000002 OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the TRANSLATION *Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials number(s), publisher, city and/or country where published NO 1. Salanoubat, et al., "Genome Sequence of the Plant Pathogen Ralstonia solanacearum", Nature, Vol. П 415, No. 6871, pg. 497-502, January 31, 2002. 2. EMBL Accession No. AAE04797, September 10, 2001, "Human Aspartyl Protease (ASP-2) from П clone 1869868." П Fujiwara, et al., "Neutrophil Elastase: A Candidate Antigen for Adoptive T Cell Therapy for Myeloid П 3. Leukemia?", Blood, Vol. 100, No. 11, November 16, 2002, pg. 677a, Abstract No. 2666, 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, USA; December 6-10, 2002. Zohar, et al., "Quantification and Distribution of β-secretase Alternative Splice Variants in the Rat and 4. Human Brian", Molecular Brain Research, Vol. 115, pg. 63-68, 2003. Tanahashi, et al., "Three Novel Alternatively Spliced Isoforms of the Human Beta-Site Amyloid П 5. Precursor Protein Cleaving Enzyme (BACE) and their Effect on Amyloid Beta-Peptide Production", Neuroscience Letters, Vol. 307, pg. 9-12, 2001. 6. Ehehalt, et al., "Splice Variants of the β-Site APP-cleaving Enzyme BACE1 in Human Brain and Pancreas", Biochemical and Biophysical Research Communications, Vol. 293, pg. 30-37, 2002. 7. Turner III, et al., "Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design", Biochemistry, Vol. 40, No. 34, pg. 10001-10006, 2001. 8. Hom, et al., "Design and Synthesis of Statine-Based Cell-Permeable Peptidomimetic Inhibitors of Human β-Secretase", J. Med. Chem., Vol. 46, pg. 1799-1802, 2003. П **EXAMINER SIGNATURE** DATE CONSIDERED *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not

in conformance and not considered. Include copy of this form with next communication to applicant.